

Special Issue

Antimicrobial Therapeutics for Bone and Periprosthetic Joint Infection

Message from the Guest Editors

Osteomyelitis and periprosthetic joint infections (PJIs) have gained interest in the last decades. While the surgical part of the management of such infections is based on general rules generally well admitted, it is not the case for the antimicrobial part. Indeed, the numerous antimicrobial agents including new antibiotics result in a huge number of potential antimicrobial regimens. Recent studies have highlighted the potential role of bacteria in the recurrence of osteomyelitis which might result in another possible way to fight against this issue. Suppressive antimicrobial therapy is used by some teams but it still needs clarification in its definition and modalities of administration. The question of both duration and oral administration of antimicrobial therapy for osteomyelitis and PJIs has been addressed. This Special Issue seeks manuscript submissions that further our understanding of antimicrobial therapy for osteomyelitis and PJIs. Submissions on new antimicrobial approaches especially bacteriophages, prevention of recurrence, and innovative antimicrobial regimens are especially encouraged.

Guest Editors

Prof. Dr. Éric M. Senneville

Service de Maladies Infectieuses et Tropicales, Centre Hospitalier de Tourcoing, 59200 Tourcoing, Nord-Pas-de-Calais, France

Dr. Olivier Robineau

Service de Maladies Infectieuses et Tropicales, Centre Hospitalier de Tourcoing, 59200 Tourcoing, Nord-Pas-de-Calais, France

Deadline for manuscript submissions

closed (31 October 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/147921

Antibiotics

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(General Pharmacology, Toxicology and Pharmaceutics)